Alpine Immune Sciences (NASDAQ:ALPN) Sets New 52-Week High at $64.72

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) shares hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $64.72 and last traded at $64.70, with a volume of 748953 shares changing hands. The stock had previously closed at $64.64.

Analyst Ratings Changes

A number of analysts have commented on ALPN shares. Guggenheim started coverage on shares of Alpine Immune Sciences in a research report on Tuesday, April 9th. They set a “buy” rating and a $55.00 price target on the stock. Wedbush downgraded Alpine Immune Sciences from an “outperform” rating to a “neutral” rating in a research report on Thursday, April 11th. Morgan Stanley reiterated an “equal weight” rating and set a $65.00 price target (up from $47.00) on shares of Alpine Immune Sciences in a research report on Thursday, April 11th. HC Wainwright lowered Alpine Immune Sciences from a “buy” rating to a “neutral” rating in a report on Thursday, April 11th. Finally, Wolfe Research reaffirmed a “peer perform” rating on shares of Alpine Immune Sciences in a report on Thursday, April 11th. Eight investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, Alpine Immune Sciences currently has a consensus rating of “Hold” and an average target price of $50.33.

Alpine Immune Sciences Price Performance

The firm has a market capitalization of $4.24 billion, a PE ratio of -101.09 and a beta of 0.97. The firm has a fifty day moving average price of $48.01 and a 200 day moving average price of $29.53.

Alpine Immune Sciences (NASDAQ:ALPN) last posted its quarterly earnings data on Monday, March 18th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.47. The company had revenue of $30.85 million during the quarter, compared to analyst estimates of $6.90 million. Alpine Immune Sciences had a negative net margin of 54.66% and a negative return on equity of 15.54%. On average, sell-side analysts expect that Alpine Immune Sciences, Inc. will post -1.74 EPS for the current year.

Hedge Funds Weigh In On Alpine Immune Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. purchased a new stake in shares of Alpine Immune Sciences in the first quarter valued at $27,000. Allspring Global Investments Holdings LLC raised its position in Alpine Immune Sciences by 745.5% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,488 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 1,312 shares during the period. AJOVista LLC purchased a new stake in Alpine Immune Sciences in the 4th quarter worth about $64,000. Barclays PLC boosted its position in Alpine Immune Sciences by 44.3% during the 3rd quarter. Barclays PLC now owns 9,126 shares of the biotechnology company’s stock worth $104,000 after acquiring an additional 2,801 shares during the period. Finally, Tower Research Capital LLC TRC grew its stake in Alpine Immune Sciences by 411.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,490 shares of the biotechnology company’s stock valued at $105,000 after acquiring an additional 4,417 shares in the last quarter. Institutional investors and hedge funds own 75.17% of the company’s stock.

Alpine Immune Sciences Company Profile

Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.